GM-2505, a novel 5-HT2A receptor agonist

https://journals.sagepub.com/doi/10.1177/02698811251378512?utm_source=researchgate.net&utm_medium=article

GM-2505 is a novel 5-HT2A receptor agonist. Given the ability of other 5-HT2A agonists to rapidly induce long-term remission in MDD, it is plausible that GM-2505 may produce similar results. Notably, in comparison to DMT, LSD, and psilocybin, it has a significantly shorter duration. This reduction in duration may create additional psychotherapeutic ‘leverage’. For example, the relatively short half-life of DMT could complexify target engagement and minimize the availability of meaningful clinical intervention during the duration of the experience. Similarly, the long half-life of substances like LSD and psilocybin may complicate the timing and structure of therapeutic engagement. A faster onset and briefer resolution phase may provide a less burdensome experience and a more manageable therapeutic window. 

I believe that GM-2505’s relatively quick onset and resolution phase could provide a more suitable clinical structure for several reasons. It may reduce some of the anticipatory anxiety associated with longer onsets and allow a smoother transition into the ‘peak’, which is often described as the most therapeutically meaningful portion of the experience. This reduction in total duration could function to remove barriers for those who report difficulty tolerating the longer-term presence of psychedelic effects. This could reduce negative affect for some patients by making the experience feel more contained. Although intensity itself is intrinsic to the psychedelic experience, a slight reduction may increase overall availability to patients who have historically presented with uncertainty, allowing a greater portion of the population to theoretically remit from negative symptoms. 

I also believe that clinical intervention may be impacted meaningfully by a reduction in the total duration of the experience. Practically speaking, an onset of twenty minutes after dosing will shorten the time required by clinicians and providers. The total duration may be nearly half that of LSD and psilocybin. This may provide the patient and clinician with a more precise window of time in which to engage the therapeutic target, which could minimize both patient-side and clinician-side confusion and guesswork on timing. This might allow sessions to function with increased clarity and punctuality, and resembles something closer to a therapy ‘session’ rather than an all-day excursion.